The β2‐Glycoprotein I/HLA–DR Complex As a Major Autoantibody Target in Obstetric Antiphospholipid Syndrome
- 24 June 2020
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatology
- Vol. 72 (11), 1882-1891
- https://doi.org/10.1002/art.41410
Abstract
Objectives The clinical manifestations of antiphospholipid syndrome (APS) include vascular thrombosis and pregnancy morbidity, including recurrent pregnancy loss (RPL). However, more than half of RPL patients never determine the cause of their RPL. Recently, β2‐glycoprotein I (β2GPI) complexed with human leukocyte antigen class II molecules (β2GPI/HLA‐II) was found to be a major autoantibody target in APS. In this study, autoantibodies against the β2GPI/HLA‐II complex were analyzed in women with RPL, which is a clinical symptom of obstetric APS. Methods Serum levels of antiphospholipid antibodies (aPL), including immunoglobulin (Ig) G/IgM anti‐cardiolipin antibody, IgG/IgM anti‐β2GPI antibody, and lupus anticoagulant, as well as anti‐β2GPI/HLA‐DR antibodies were measured in 227 women with RPL. In this prospective, multicenter, cross‐sectional study, women with RPL and their partners underwent HLA‐DR immunotyping and analysis to identify potential causes and risk factors associated with RPL. The normal range for anti‐β2GPI/HLA‐DR antibody levels was obtained from 208 fertile women used as controls. Results aPL was detected in 19.8% of women with RPL. Fifty‐two out of the 227 (22.9%) women with RPL tested positive for anti‐β2GPI/HLA‐DR antibodies, and 24 out of the 121 (19.8%) women with unexplained RPL were positive for anti‐β2GPI/HLA‐DR antibodies. Twenty‐one out of 112 (18.8%) women, who had clinical symptoms of APS but not aPL of criteria, tested positive for anti‐β2GPI/HLA‐DR antibodies. Conclusions The anti‐β2GPI/HLA‐DR antibody is frequently associated with RPL. Detection of these autoantibodies is useful in understanding the pathogenesis of RPL. Our findings will potentially provide new therapeutic modalities for patients with obstetric APS.Funding Information
- Japan Society for the Promotion of Science (JP17K11235, JP18H05279, JP18K19450)
- Ministry of Education, Culture, Sports, Science and Technology (JP190H04808)
- Japan Agency for Medical Research and Development (JP17fm0208004, JP18gk0110018, JP19ek0410053, JP19gk0110047)
This publication has 35 references indexed in Scilit:
- New insights into mechanisms behind miscarriageBMC Medicine, 2013
- Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodiesArthritis & Rheumatism, 2012
- Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective studyBlood, 2011
- Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic eventsArthritis & Rheumatism, 2011
- Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control studyRheumatology, 2011
- β2-Glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndromeBlood, 2010
- Diagnostic factors identified in 1020 women with two versus three or more recurrent pregnancy lossesFertility and Sterility, 2010
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Journal of Thrombosis and Haemostasis, 2006
- Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface.The Journal of Experimental Medicine, 1994
- Mhc Gene Products and Anticardiolipin Antibodies in Systemic Lupus Erythematosus Results of a Multicenter StudyAutoimmunity, 1992